There has been expectation that the antibody could be made available at a discount to Merck & Co's PD-1 inhibitor Keytruda (pembrolizumab), which dominates first-line NSCLC treatment, offering an ...

BeiGene confirmed today that Novartis has pulled out of a partnership on PD-1 inhibitor tislelizumab, two and half years after paying $650 million upfront for ex-China rights to the cancer ...

BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...

Aethlon Medical has enrolled the first patient in its Australian clinical trial evaluating the safety, feasibility, and ...

Celldex Therapeutics has halted work on its solid-tumor-focused bispecific as the biotech prioritizes its work in ...

Jeffrey Meckler, Indaptus Therapeutics ’ Chief Executive Officer, commented, “The recent announcement highlighting our clinical supply agreement with BeiGene is an important m ...

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract cancers (BTC); ...

The company said it would also explore combinations of BNT327/PM8002 and its antibody-drug conjugates (ADC ... The move ...

OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today announced the results of the Phase 1 trial of OR502, a novel, ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...